Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim
Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-centre, fixed-sequence, open label, drug-drug interaction study in
2 groups of healthy subjects.
Group A: to evaluate the effects of itraconazole, a strong inhibitor of cytochrome P450 3A
(CYP3A), upon the pharmacokinetics of olorofim .
Group B: t o evaluate the effects rifampicin, a strong inducer of CYP3A, upon the
pharmacokinetics of olorofim .